Answers are grounded in this paper and cite their sources.
Observational study shows liso-cel improves response rates in patients with relapsed or refractory CLL, suggesting it as a viable treatment option.
7024 Background: Liso-cel is an autologous, CD19-directed CAR T cell product with established efficacy and safety across B-cell malignancies. In TRANSCEND CLL 004 (NCT03331198), liso-cel demonstrated promising efficacy and manageable safety in pts with R/R CLL, including those previously exposed to Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i). Here, we report real-world effectiveness and safety of liso-cel in pts with R/R CLL. Methods: This observational study evaluated US pts with R/R CLL who received commercial liso-cel (05/2024–09/2025) and had ≥ 1 postinfusion assessment reported to CIBMTR. Effectiveness outcomes were ORR, CR rate, duration of response (DOR), PFS and OS; safety outcomes included AEs of special interest, nonrelapse mortality (NRM) and death. Results are descriptive. Results: Of 45 eligible pts, 64% were male; median age was 62 y (range, 44–83; ≥ 65 y, 44%). In pts with available data, all had ECOG PS 0–1 (43/43) and 57% (21/37) had ≥ 1 comorbidity, most commonly (> 10%) cardiac (24%) or pulmonary (16%). Elevated LDH was observed in 35% (15/43) and unmutated IGHV in 91%. Pts had a median of 6 (range, 1–10) prior therapies and 71% received liso-cel as fifth-line or later treatment (tx). Most pts (84%) were previously exposed to covalent BTKi and BCL2i, and nearly half (47%) had prior pirtobrutinib tx. Bridging therapy was used in 48% (21/44) of pts. At a median (95% CI) follow-up of 6.0 mo (5.4–7.1), ORR was 84% (70–93), and CR rate was 55% (39–70); 81% (13/16) of pts in CR with available data were MRD negative. Median (95% CI) DOR, PFS, and OS were not reached. Among responders (n = 36), 6-mo DOR was 89% (70–96.5); 6-mo PFS and OS were 77% (60–87) and 87% (72–95), respectively. Among pts with any-grade (gr) cytokine release syndrome (80%; gr ≥ 3, 4%) or immune effector cell–associated neurotoxicity syndrome (36%; gr ≥ 3, 13%), no gr 5 events occurred. Clinically significant infections were reported in 40% of pts, and at 30 d after infusion, 18% had persistent gr 4 thrombocytopenia and/or neutropenia. Rates were low of HLH/MAS (7%), second primary malignancies (2%; 1 case of basal cell carcinoma 34 d postinfusion), tumor lysis syndrome (7%), and gr 3/4 organ toxicity (9%). Of the 5 deaths, 2 each were due to relapse/progression or infection, and 1 pt had multiple causes reported; 6-mo NRM was 5% (95% CI, 0.8–14). Among the 49% of pts intended for outpatient infusion, 55% (12/22) were hospitalized postinfusion, with a median (range) time to hospitalization of 5.5 d (1–20) and a stay of 5.5 d (1–26). Conclusions: In routine clinical practice, liso-cel demonstrated response rates higher than in clinical trials, with a consistent safety profile. These real-world data support liso-cel as an effective option for pts with R/R CLL, including heavily pretreated or high-risk pts, and the potential for outpatient administration.
No takes yet. Share an insight, caveat, or question.
Tomasulo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: